1193784-36-9

Upstream product

• 108-98-5 thiophenol 
• 155417-78-0 (3R,4S,5R,6R)-6-(acetoxymethyl)-4-azidotetrahydro-2H-pyran-2,3,5-triyl triacetate 
• 155417-78-0 (2S,3R,4S,5R,6R)-6-(acetoxymethyl)-4-azidotetrahydro-2H-pyran-2,3,5-triyl triacetate 
• 71676-30-7 phenyl 4,6-di-O-benzylidene-1-thio-β-D-galactopyranoside 
• 1185735-67-4 phenyl 2-O-acetyl-4,6-O-benzyliden-1-thio-β-D-gulopyranoside 
• 1185735-69-6 phenyl 2-O-acetyl-3-azido-4,6-O-benzylidene-3-deoxy-1-thio-β-D-galactopyranoside 
• 1185735-68-5 phenyl 2-O-acetyl-4,6-O-benzylidene-1-thio-3-O-trifluoromethanesulfonyl-β-D-gulopyranoside 
• 1193784-34-7 phenyl 2-O-acetyl-4,6-O-benzylidene-1-thio-3-O-trifluoromethanesulfonyl-β-D-galactopyranoside 
• 138922-03-9 phenyl 4,6-O-benzylidene-1-thio-β-D-galactopyranoside 
• 1193784-35-8 phenyl 2-O-acetyl-3-azido-3-deoxy-1-thio-β-D-galactopyranoside 
• 108-24-7 acetic anhydride 

Downstream Products

• 1450824-22-2 (2R,2'R,3R,3'R,4S,4'S,5R,5'R,6S,6'S)-6,6'-sulfanylbis(4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol) 
• 155417-78-0 (2S,3R,4S,5R,6R)-6-(acetoxymethyl)-4-azidotetrahydro-2H-pyran-2,3,5-triyl triacetate 

Relevant academic research and scientific papers

GALECTIN-3 INHIBITING C-GLYCOSIDE KETONES, ETHERS, AND ALCOHOLS

The application relates to galectin-3 inhibitors of Formula (I), to pharmaceutical compositions comprising them, and their medical use for the treatment and/or prevention of diseases or disorders such as inflammatory diseases, fibrosis, neurodegeneration, thrombosis and cancer.

SELECTIN OR GALECTIN ANTAGONISTS FOR TREATING CYTOKINE RELEASE SYNDROME AND CRS-INDUCED NEUROTOXICITY

Methods and compounds for the treatment and/or prevention of CRS and/or CRS-induced neurotoxicities using at least one selectin antagonist are disclosed. The disclosed methods and compounds use at least one of the disclosed antagonists to target and reduce cytokine expression and/or endothelial activation to treat and/or prevent CRS and/or CRS-related conditions such as CRS-induced neurotoxicities.

HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTIN AND GALECTIN-3

Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands are disclosed. For example, heterobifunctional inhibitors of E-selectin and galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.

GALECTIN-3 INHIBITING C-GLYCOSIDES

Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of galectin-3 to ligands are disclosed. For example, inhibitors of galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.

METHODS OF TREATING HIV AND AIDS AND THE ELIMINATION OF LATENT RESERVOIRS OF HIV INFECTION USING SELECTIN, GALECTIN, AND SIGLEC ANTAGONISTS

Methods and compounds for the treatment of HIV and/or AIDS using selectin antagonists, galectin-9 antagonists, and/or Siglec-7 antagonists are disclosed. The disclosed methods and compounds use the disclosed antagonists to target and eliminate quiescent reservoirs of infected cells to treat and/or cure this infection.

ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS

The present invention relates to a compound of the general formula (1). wherein the pyranose ring is a-D-galactopyranose, A is selected from The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore the present invention concerns compounds for use in a method of treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

GALACTOSIDE INHIBITORS FOR THE TREATMENT OF ALPHA-SYNUCLEINOPTHIES

The present invention relates to a pharmaceutical composition for use in a method for treatment or prevention of a-synucleinopathies wherein the composition comprises a molecule for pharmacological modulation of galectin activity in a mammalian brain. The

Novel Galactoside Inhibitor of Galectins

The present invention relates to a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method of monitoring development or progression of pulmonary fibrosis in a human subject, a method of monitoring or predicting exacerbation of symptoms in a human subject with pulmonary fibrosis as well as a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms.

METHODS, COMPOSITIONS AND KITS FOR TREATING, MODULATING, OR PREVENTING OCULAR ANGIOGENESIS OR FIBROSIS IN A SUBJECT USING A GALECTIN PROTEIN INHIBITOR

Methods and kits using a pharmaceutical composition for use in inhibiting ocular angiogenesis or fibrosis are provided herein, such that composition includes a pharmaceutically suitable carrier or diluent and an amount of the inhibitor composition effective to inhibit the angiogenesis or the fibrosis by inhibiting expression and/or activity of a galectin protein or a portion thereof.

NOVEL SYNTHESIS OF GALACTOSIDE INHIBITORS

The present invention relates to novel synthesis routes for preparation of thiodigalactosides of the general formula (12). The method comprises the use of a 3-azido-galactosyl thiouronium salt derivative, which is activated to the corresponding thiol in s